Marina Barreto Felisbino

Dr. Marina Barreto Felisbino


Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 February 2016 in Journal of Cellular Physiology
Verified
Journal Article
Closed access
PDF file
MFMarina Barreto Felisbino
Marina Barreto Felisbino
TCThiago Alves da Costa
Thiago Alves da Costa
MGMaria Silvia Viccari Gatti
Maria Silvia Viccari Gatti
MMMaria Luiza Silveira Mello
Maria Luiza Silveira Mello

25 January 2018 in bioRxiv
Verified
Preprint
Open access
PDF file
MFMarina Barreto Felisbino
Marina Barreto Felisbino
MZMark Ziemann
Mark Ziemann
IKIshant Khurana
Ishant Khurana
COCamila Borges Martins de Oliveira
Camila Borges Martins de Oliveira
MMMaria Luiza Mello
Maria Luiza Mello
AEAssam El-Osta
Assam El-Osta
Atherothrombosis remains the leading cause of morbidity and mortality in patients diagnosed with diabetes mellitus, but the molecular mechanisms underpinning this remain unresolved. As the liver plays a major role in metabolic homeostasis and secretion of clotting factors and inflammatory innate immune proteins, there is an interest in understanding the mechanisms of hepatic cell activation under hyperglycemia and whether this can be attenuated pharmacologically. We have previously shown that hyperglycemia stimulates major changes in chromatin organisation and metabolism in hepatocytes, and that the histone deacetylase inhibitor valproic acid (VPA; IUPAC: 2-propylpentanoic acid) is able to reverse some of these metabolic changes. In this study, we used deep transcriptome sequencing to show that VPA attenuates hyperglycemia-induced activation of complement and coagulation cascade genes. These findings reveal a novel mechanism of VPA protection against hyperglycemia, which might improve the therapeutic approaches for diabetes.